

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of Risk Management Plan for Dapagliflozin/Metformin Viatris and DAFORBIS PLUS (dapagliflozin/metformin)

This is a summary of the risk management plan (RMP) for Dapagliflozin/Metformin Viatris and DAFORBIS PLUS. The RMP details important risks of Dapagliflozin/Metformin Viatris and DAFORBIS PLUS, how these risks can be minimised, and how more information will be obtained about Dapagliflozin/Metformin Viatris and DAFORBIS PLUS' risks and uncertainties (missing information).

Dapagliflozin/Metformin Viatris and DAFORBIS PLUS summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how it should be used.

Important new concerns or changes to the current ones will be included in updates of Dapagliflozin/Metformin Viatris and DAFORBIS PLUS' RMP.

I. The Medicine and What it is Used For

Dapagliflozin/Metformin Viatris and DAFORBIS PLUS is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise:

- in patients insufficiently controlled on their maximally tolerated dose of metformin alone
- in combination with other medicinal products for the treatment of diabetes in patients insufficiently controlled with metformin and these medicinal products
- in patients already being treated with the combination of dapagliflozin and metformin as separate tablets.

It contains dapagliflozin and metformin as the active substances and it is given via the oral route.

II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks

Important risks of Dapagliflozin/Metformin Viatris and DAFORBIS PLUS, together with measures to minimise such risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific Information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the public (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse events is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of Important Risks and Missing Information

Important risks of Dapagliflozin/Metformin Viatris and DAFORBIS PLUS are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken by patients. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Dapagliflozin/Metformin Viatris and DAFORBIS PLUS. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine/use in special patient populations etc.);

Table 3: Part VI.1- Summary of safety concerns

List of Important Risks and Missing Information	
Important Identified Risks	Lactic acidosis (metformin) Diabetic Ketoacidosis including events with atypical presentation (dapagliflozin)
Important Potential Risks	None
Missing Information	None

II.B Summary of Important Risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-Authorisation Development Plan

II.C.1 Studies Which are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Dapagliflozin/Metformin Viatris and DAFORBIS PLUS.

II.C.2 Other Studies in Post-Authorisation Development Plan

There are no studies required for Dapagliflozin/Metformin Viatris and DAFORBIS PLUS.